ArticleThe Journal of clinical investigation2022

Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle.

Se Jin Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.